Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Zonsen PepLib Biotech

    • Home
    • Zonsen PepLib Biotech
Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Fineline Cube Jan 12, 2026

Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset...

Recent updates

  • Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO
  • Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform
  • Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study
  • Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution
  • FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.